A Phase Ib Multiple Ascending Dose Study of BMS-833923 Alone or in Combination With Lenalidomide (Revlimid) Plus Dexamethasone or in Combination With Bortezomib (Velcade) in Subjects With Relapsed or Refractory Multiple Myeloma.

Trial Profile

A Phase Ib Multiple Ascending Dose Study of BMS-833923 Alone or in Combination With Lenalidomide (Revlimid) Plus Dexamethasone or in Combination With Bortezomib (Velcade) in Subjects With Relapsed or Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2012

At a glance

  • Drugs BMS 833923; Bortezomib; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 31 Dec 2011 Primary endpoint identified as (recommended phase II dose) as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top